Chasing leaders, Juno rides CAR-T momentum into ASH – BioPharma Dive
|
Chasing leaders, Juno rides CAR–T momentum into ASH
BioPharma Dive For a field that not too long ago was considered science fiction, CAR–T cell therapy has transitioned from the clinic to the market in remarkable speed. This year’s annual meeting of the American Society of Hematology (ASH), set to kick off Saturday … |
FierceBiotech |
Gilead, Kite to Acquire Cell Design Labs for Up-to-$567M, Growing CAR–T Footprint
Genetic Engineering & Biotechnology News Gilead Sciences and its Kite cell therapy subsidiary have agreed to acquire Cell Design Labs for up to approximately $567 million, in a deal designed to grow the buyers’ footprint in chimeric antigen receptor T cell (CAR-T) and other cellular therapies … Gilead deepens CAR–T push with deal for Cell DesignBioPharma Dive Gilead makes bolt-on CAR–T buy after Kite dealFierceBiotech Gilead swoops in with $567M deal to buy CAR-T 2.0 player Cell …Endpoints News Xconomy –San Francisco Business Times –MIT Technology Review all 25 news articles » |
|
CAR:T – Has biology outpaced the ability to deliver?
pharmaphorum Adapter CAR Program Manager. “The use of universal T cells might be the right tool to overcome shortage? First trials are promising…There’s emerging of companies doing exciting work with using renewable master to develop pluripotent stem cell lines … |